BRAVO, CRUISE studies show benefits of early retinal vein occlusion treatment

Early treatment with ranibizumab significantly improved vision in patients treated for retinal vein occlusion, according to a post-hoc analysis of two major studies. Data were culled from the BRAVO and CRUISE studies. Patients received Lucentis (ranibizumab, Genentech) 0.3 mg or 0.5 mg for 6 months, then on an as-needed basis (PRN) according to re-treatment protocols.

Full Story →